Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS

(FRE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius, Fresenius Medical Care Shares Fall on Revised Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 04:40am EST

By Patrick Costello

Shares of Fresenius fell sharply Friday morning after the German healthcare provider adjusted its midterm guidance and warned it would miss its 2020 group targets late Thursday.

Fresenius said it expects to see mid-single-digit organic sales growth for 2019 compared with earlier forecasts that had group sales increasing at a compounded annual growth rate, or CAGR, of 7.1% to 10.3% through 2020.

Net income for 2019 would remain "broadly stable" compared with 2018, Fresenius said. Its previous forecasts saw group net income increasing at a CAGR of 8.3% to 12.6% through 2020.

At GMT 0910, Fresenius SE was 10% lower at EUR42.56. The company is down nearly 34% in the year to date.

Shares of Fresenius Medical Care, a provider of dialysis products and services that is partially owned by Fresenius SE, also fell Friday after it said 2019 sales growth and net income would be in line with levels recorded in 2018.

Fresenius Medical Care's shares were down 6.9% at EUR63.38.

Bryan Garnier said both companies' shares will remain under pressure until they release more detailed guidance along with full-year earnings Feb. 20.

Fresenius's decision to revise its 2020 targets is "no surprise whatsoever," Berenberg said, adding that the existing 2020 targets had already been rendered "completely meaningless" due to events like the divestiture of Sound and the pending acquisition of NxStage.

The revised forecasts should be taken positively once investors work out the implications, the bank said.

Write to Patrick Costello at Patrick.Costello@dowjones.com.

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS -0.56% 49.88 Delayed Quote.18.26%
FRESENIUS MEDICAL CARE -0.14% 70.38 Delayed Quote.24.47%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
02/20EUROPE : Trade talks keep European shares afloat as Sainsbury's, Swedbank sink
RE
02/20FMC expects NxStage deal to close in next couple of days
RE
02/20Fresenius Backs 2019 Outlook, Hopeful About Future
DJ
02/20FRESENIUS MEDICAL CARE : Announces Share-Buyback Program of Up to EUR1 Billion
DJ
01/31FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
01/31FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
01/29FRESENIUS MEDICAL CARE : FMC extends deadline for NxStage deal until Aug. 6 due ..
RE
01/29FRESENIUS MEDICAL CARE : NxStage Postpone Merger End Date Due to Shutdown
DJ
01/25FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
01/24EUROPE : Downbeat Draghi curbs gains on European shares as tech shines
RE
More news
Financials (€)
Sales 2019 34 871 M
EBIT 2019 4 676 M
Net income 2019 1 883 M
Debt 2019 15 122 M
Yield 2019 1,62%
P/E ratio 2019 14,95
P/E ratio 2020 14,07
EV / Sales 2019 1,23x
EV / Sales 2020 1,14x
Capitalization 27 876 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 55,6 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS18.26%31 610
IHH HEALTHCARE BHD--.--%12 312
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 212
AIER EYE HOSPITAL GROUP CO LTD--.--%11 123
RAMSAY HEALTH CARE LIMITED3.46%8 537
PREMIER INC0.80%4 926